The latest offering puts the genetic testing company on the path toward becoming what it calls a preventive health service company.
Illumina received more orders than expected for NovaSeq in Q2 and sees a big opportunity in the consumer genomics market for its array business and Helix.
Parent firm Gene by Gene calls the law "brief and vague" and is pushing for ancestry testing to be exempt from the provision of the genetic privacy statute.
Among the initial crop of products there may not be a killer app yet, but these first offerings will enable Helix and partners to begin to understand their customer base.
With choice, real-time interpretation, low pricing, and education, Helix believes it may have cracked the formula for integrating genomics into people's daily lives.
NantOmics hopes to enhance its diagnostics platform with the addition of Genos' sequencing technology and expertise.
With the $250 service, Color is hoping to broaden access to genetic testing and make it easier for researchers to incorporate genetics in their studies.
Launching a diverse product pipeline will also test Helix's ability to manage the challenges of providing genomics interpretations to a broad consumer audience.
The consumer genomics firm Helix will use an FDA-cleared device from OraSure's subsidiary DNA Genotek for collecting DNA samples from customers.
The new assay, called the CellMax-DNA Genetic Cancer Risk Test, will complement CellMax Life's planned slate of liquid biopsy assays for early cancer detection.
The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.
Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.
A Washington Post columnist writes that she is skeptical about DNA-based diets.
In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.